| Literature DB >> 26927058 |
Sung Won Hwang1, Yoon-Mi Lee2,3, Giancarlo Aldini4, Kyung-Jin Yeum5,6.
Abstract
Reactive carbonyl species generated by the oxidation of polyunsaturated fatty acids and sugars are highly reactive due to their electrophilic nature, and are able to easily react with the nucleophilic sites of proteins as well as DNA causing cellular dysfunction. Levels of reactive carbonyl species and their reaction products have been reported to be elevated in various chronic diseases, including metabolic disorders and neurodegenerative diseases. In an effort to identify sequestering agents for reactive carbonyl species, various analytical techniques such as spectrophotometry, high performance liquid chromatography, western blot, and mass spectrometry have been utilized. In particular, recent advances using a novel high resolution mass spectrometry approach allows screening of complex mixtures such as natural products for their sequestering ability of reactive carbonyl species. To overcome the limited bioavailability and bioefficacy of natural products, new techniques using nanoparticles and nanocarriers may offer a new attractive strategy for increased in vivo utilization and targeted delivery of bioactives.Entities:
Keywords: bioefficacy; nanotechniques; natural products; reactive carbonyl species
Mesh:
Substances:
Year: 2016 PMID: 26927058 PMCID: PMC6273166 DOI: 10.3390/molecules21030280
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of reactive carbonyl species: α,β-unsaturated aldehydes (A); keto-aldehyde (B) and di-aldehydes (C).
Studies targeting reactive carbonyl species to prevent metabolic disorders.
| Metabolic Disorders | Targeting RCS | Tested Agent | Model | Ref. |
|---|---|---|---|---|
| Insulin resistance | HNE, Protein carbonyls | D3T, NAC, AGD, SAM | Gastrocnemius muscle, muscle cells (L-6) | [ |
| Insulin resistance | AGEs, Protein carbonyls | AGD, Pyridoxamine | Pancreatic β-cells (HIT-T15) | [ |
| Diabetic nephropathy | RAGE | Glucagon-like peptide 1 | Human mesangial cells | [ |
| Dyslipidemia | HNE, AGEs | Carnosine | Zucker Fa/Fa rats | [ |
| Atherosclerosis Renal disease | HNE, ALEs | D-carnosine octylester | ApoE null mice (HFD) | [ |
| Diabetic atherosclerosis | RCS, AGEs, ALEs, RAGE | LR-90 | Streptozotocin induced diabetic rats | [ |
| Liver damage | AGEs, RAGE, protein carbonyls | Glycyrrhizi | High fructose-fed Wistar rats | [ |
| Liver/renal toxicity | RAGE, Protein carbonyls | Peach | CCl4 injected Wistar rats | [ |
| Diabetic nephropathy | RAGE | Candesartan | MG injected Dahl salt-sensitive rats | [ |
| Diabetes and complication | RAGE | Simvastatin | Type 2 diabetic patients | [ |
| Diabetes | MG | Metformin | Type 2 diabetic patients | [ |
RCS, reactive carbonyl species; HNE, 4-hydroxy-trans-2-nonenal; D3T, 3H-1,2-dithiole-3-thione; NAC, N-acetyl-cysteine; AGD, aminoguanidine; SAM, S-adenosylmethionine; AGEs: advanced glycation end products; RAGE, receptor for advanced glycation end products; ALEs, advanced lipoxidation end products; HFD, high fat diet; MG, methyl glyoxal.
Studies targeting reactive carbonyl species to prevent neurodegenerative diseases.
| Neurodegenerative Diseases | Targeting RCS | Tested Agent | Model | Ref. |
|---|---|---|---|---|
| Neuronal damage | MDA, AGE-RAGE, Protein carbonyls | EGCG | AGE treated SH-SY5Y cells | [ |
| Neuronal damage | MDA, Protein carbonyls | Notoginsenoside | H2O2 treated PC12 cells | [ |
| Brain inflammation | AGEs, RAGE, Protein carbonyls | Ursolic acid | D-galactose injected Kunming mice | [ |
| Neuronal damage | MDA, Protein carbonyls | Melatonin | 56F-irradiated C57BL mice | [ |
| Alzheimer’s disease | AGEs, Protein carbonyls | Troxerutin | High cholesterol fed C57BL/6 mice | [ |
| Alzheimer’s disease | HNE | Antisense oligonucleotide | SAMP8 mice | [ |
| Alzheimer’s disease | HNE, Protein carbonyls | Curcumin | Streptozotocin-injected Wistar rats | [ |
| Alzheimer’s disease | HNE, Protein carbonyls | Ferulic acid ethyl ester | AAPH or Fe2+/H2O2 injected Mongolian gerbils | [ |
| Cognitive dysfunction | HNE, Protein carbonyls | 2-Mercaptoethane sulfonate | doxorubicin-received patients | [ |
RCS, reactive carbonyl species; AGEs: advanced glycation end products; RAGE, receptor for advanced glycation end products; EGCG, epigallocatechin gallate; AAPH, 2,2′-Azobis(2-amidinopropane) dihydrochloride; HNE, 4-hydroxy-trans-2-nonenal.
Figure 2Hypothetical cytotoxic reactive carbonyl species sequestering action of natural products. PUFA, polyunsaturated fatty acid; HNE, 4-hydroxy-trans-2-nonenal; AGEs/ALEs, advanced glycation end product/advanced lipoxidation end products; RAGE, receptor for advanced glycation end products.
Analytical techniques identifying reactive carbonyl species sequestering agents.
| Analytical Techniques | Advantages | Disadvantages | Ref |
|---|---|---|---|
| Spectrophotometry | Simple Fast | No specificity | [ |
| HPLC | Limited specificity | No application for complex mixture | [ |
| NMR spectroscopy | Molecule identification | No qunatitation | [ |
| Western blot | Semiqunatitative | Time consuming | [ |
| LC-MS | Quantitative Complex mixture analysis | Molecule identification require further analysis | [ |
HPLC, high performance liquid chromatography; NMR spectroscopy, nuclear magnetic resonance spectroscopy; LC-MS, high resolution mass spectrometry.
Figure 3Application of nano-technologies improving bioavailability of natural products. EGCg, epigallocatechin gallate.
Figure 4Structures of graphene (A); graphene oxide (B) and grapheme quantum dot (C).